在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
While she knows there is a difficult road ahead, she said she was determined to rebuild her life.
，推荐阅读safew官方下载获取更多信息
placement: “across chest height”，推荐阅读同城约会获取更多信息
Go to worldnews
* @param arr 待排序数组